Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
about
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-UpEfficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized TherapyOptimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
P2860
Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Switching to emtricitabine, te ...... cted patients: a cohort study.
@en
Switching to emtricitabine, te ...... cted patients: a cohort study.
@nl
type
label
Switching to emtricitabine, te ...... cted patients: a cohort study.
@en
Switching to emtricitabine, te ...... cted patients: a cohort study.
@nl
prefLabel
Switching to emtricitabine, te ...... cted patients: a cohort study.
@en
Switching to emtricitabine, te ...... cted patients: a cohort study.
@nl
P2093
P2860
P356
P1433
P1476
Switching to emtricitabine, te ...... cted patients: a cohort study.
@en
P2093
C Bernard-Henry
E de Mautort
M Baldeyrou
M Partisani
M Priester
M-L Batard
P2860
P304
P356
10.1111/HIV.12183
P577
2014-08-15T00:00:00Z